Analysed ICECURE MEDICAL LTD (ICCM:NASDAQ) News Sources
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
06-07-2026
yahoo.com
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
14-07-2026
yahoo.com
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
27-07-2026
yahoo.com
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
05-08-2026
yahoo.com
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
12-08-2026
yahoo.com
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
13-08-2026
yahoo.com
Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as US ...
20-08-2026
yahoo.com
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
24-08-2026
yahoo.com
What is the current price of ICECURE MEDICAL LTD (ICCM:NASDAQ)?
The current price of ICECURE MEDICAL LTD (ICCM:NASDAQ) is $2.21.
ICECURE MEDICAL LTD (ICCM:NASDAQ) absolute price change since previous trading day?
The absolute price change of ICECURE MEDICAL LTD (ICCM:NASDAQ) since the previous trading day is $0.07.
ICECURE MEDICAL LTD (ICCM:NASDAQ) percentage price change since previous trading day?
The percentage price change of ICECURE MEDICAL LTD (ICCM:NASDAQ) since the previous trading day is 3.271%.
What is the most recent average sentiment score for ICECURE MEDICAL LTD (ICCM:NASDAQ)?
The most recent average sentiment score for ICECURE MEDICAL LTD (ICCM:NASDAQ) is 88 out of 100.
What is the most recent average sentiment for ICECURE MEDICAL LTD (ICCM:NASDAQ)?
The most recent sentiment for ICECURE MEDICAL LTD (ICCM:NASDAQ) is .
SEC-8K** Filing Available For ICECURE MEDICAL LTD (ICCM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.